HR4638 National Commission on Scleroderma and Fibrotic diseases
This bill will establish a National Commission on Fibrotic Diseases within NIH to evaluate and to make recommendations regarding improvements to the coordination and advancement of NIH-supported research activities related to fibrosis and fibrotic diseases, which may include scleroderma as a prototypical condition that can cause fibrosis in various organs. At no additional cost to the federal government, the National Commission on Scleroderma and Fibrotic Diseases Act of 2017 establishes a national commission that will include the following:
Study of the incidence, duration and mortality rates of fibrotic diseases.
Evaluate facilities and resources for the diagnosis, prevision and treatment of fibrotic diseases.
Develop a long-range plan for the use and organization of national resources to advance research and deal with fibrotic diseases effectively.
Study of the incidence, duration and mortality rates of fibrotic diseases.
Evaluate facilities and resources for the diagnosis, prevision and treatment of fibrotic diseases.
Develop a long-range plan for the use and organization of national resources to advance research and deal with fibrotic diseases effectively.
View Comments